Advancing Multi-Gene RNA Therapies to Unlock Durable In-Vivo CAR-T Treatments for Eosinophilic Conditions
- Enable deeper, multi-pathway disease control in eosinophilic indications by using multi-gene RNA constructs that co-deliver multi-CARs and cytokine payloads
- Achieve durable, low-immunogenic expression suitable for repeat dosing through a synthetic RNA architecture optimized for chronic therapeutic applications
- Leverage modular multi-gene RNA design to support versatile therapeutic strategies and maintain flexibility for future development needs